Jennifer Lim, MD, FARVO, FASRS

The DAVIO-2 study reveals EYP-1901's potential as a 6-month treatment for neovascular AMD, matching aflibercept's vision outcomes with fewer doses.

Jennifer Lim, MD, FARVO, FASRS, discusses her ARVO presentation on sickle cell retinopathy, highlighting improvements in retinal surgery techniques and instrumentation.

Dr Jennifer Lim presents two case studies demonstrating the application of the personalized treatment interval algorithm from the YOSEMITE and RHINE clinical trials for faricimab in DME.

Dr Jennifer Lim reviews the personalized treatment algorithm in the YOSEMITE and RHINE trials for faricimab in DME, discussing visual and anatomic outcomes with the treat and extend strategy.